http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Myovant Sciences (MYOV) Enters Collaboration with Pfizer (PFE) to Develop and Commercialize Relugolix; to Receive $650M Upfront
-
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
-
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
-
Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
-
Pfizer (PFE), BioNTech (BNTX) to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
-
Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts
-
Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
-
Pfizer (PFE), BioNTech (BNTX) Confirm Authorization in the European Union for COVID-19 Vaccine
-
Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
-
Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
-
Pfizer (PFE) and BioNTech (BNTX) Confirm CHMP Positive Opinion for their COVID-19 Vaccine
-
Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
-
Pfizer (PFE), BioNTech SE (BNTX) Highlight Data on Neutralizing Antibody & T-Cell Responses from Phase 1/2 Trial with BNT162b2 Conducted in Germany
-
Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
-
U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization
-
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
-
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
-
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
Pfizer Declares First-Quarter 2021 Dividend
-
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
-
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
-
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
-
Pfizer (PFE) , BioNTech (BNTX) Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in NEJM
-
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
-
Pfizer (PFE) and BioNTech (BNTX) Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
-
Pfizer (PFE) Announces FDA Accepts for Priority Review BLA for Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older
-
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older
-
Pfizer (PFE) Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma
-
Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma
-
Pfizer (PFE), Sangamo (SGMO) Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
-
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
-
Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in Advanced HPV-Positive Cancers at ESMO IO 2020
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Approved in U.K.
-
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
-
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
-
ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with 'HIV in View'--a first-of-its-kind online HIV photography gallery
-
Pfizer (PFE), BioNTech (BNTX) Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
-
Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
-
ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery
-
Pfizer (PFE) Reports First Participant Dosing in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab
-
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
-
Pfizer (PFE), BioNTech (BNTX) to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
-
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
-
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
-
Pfizer (PFE) Announces Results from Phase 3 CROWN Trial of LORBRENA in Previously Untreated ALK-Positive Lung Cancer Published in the NEJM
-
Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine

